Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
Staphylococcus aureus is a ubiquitous bacterial species that causes serious disease in certain settings. S. aureus disease is difficult to treat, and antibiotic-resistant strains have become common. A vaccine to protect against infection would therefore be beneficial. However, the virulence of S. aureus is determined by a number of different factors, which makes design of a widely effective vaccine difficult. Here, various bacterial virulence factors and attempts to develop vaccines based on these factors are briefly reviewed. In particular, the success of a Phase 3 clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 is discussed.
Shinefield
Henry R
HR
Pediatrics and Dermatology, University of California, San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA. henryshinefield@aol.com
D000942:Antigens, Bacterial; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000737:chemistry / Q000276:immunology*; D013203:Staphylococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology / Q000472:pathogenicity; D018074:Vaccines, Conjugate / Q000276:immunology; D037521:Virulence Factors / Q000276:immunology
D000942:Antigens, Bacterial; D011135:Polysaccharides, Bacterial; D013209:Staphylococcal Vaccines; D018074:Vaccines, Conjugate; D037521:Virulence Factors